References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7–34.
- Novartis. Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice novartis [Online]; 2017. Available from: https://novartis.gcs-web.com/novartis-receives-fda-approval-for-KymriahTM
- Institute NC. Tisagenlecleucel (Kymriah) approved to treat some lymphomas; 2018 [cited 2019 Jul 22]. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2018/tisagenlecleucel-fda-lymphoma
- Gilead. Kite’s Yescarta™ (Axicabtagene Ciloleucel) becomes first CAR T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy gilead [Online]; 2017. Available from: http://www.gilead.com/news/press-releases/2017/10/kites-yescarta-axicabtagene-ciloleucel-becomes-first-car-t-therapy-approved-by-the-fda-for-the-treatment-of-adult-patients-with-relapsed-or-refractory-large-bcell-lymphoma-after-two-or-more-lines-of-systemic-therapy
- Novartis. Novartis receives European commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel) novartis. [Online]; 2018. Available from: https://www.novartis.com/news/media-releases/novartis-receives-european-commission-approval-its-car-t-cell-therapy-kymriah-tisagenlecleucel
- Gilead. Yescarta® (Axicabtagene Ciloleucel) receives european marketing authorization for the treatment of relapsed or refractory DLBCL and PMBCL, after two or more lines of systemic therapy | gilead. [Online]; 2018. Available from: http://www.gilead.com/news/press-releases/2018/8/yescarta-axicabtagene-ciloleucel-receives-european-marketing-authorization-for-the-treatment-of-relapsed-or-refractory-dlbcl-and-pmbcl-after-two-or-more-lines-of-systemic-therapy
- Novartis.ca. Novartis receives health Canada approval of its CAR-T cell therapy, Kymriah™ (tisagenlecleucel) novartis Canada. [Online]. Available from: https://www.novartis.ca/en/news/media-releases/novartis-receives-health-canada-approval-its-car-t-cell-therapy-kymriah
- Pmda; 2019 [cited 2019 Jul 17]. Available from: http://www.pmda.go.jp/files/000230002.pdf#page=1
- TGA. Search the TGA website; 2019 [cited 2019 Jul 17]. Available from: http://search.tga.gov.au/s/search.html?collection=tga-artg&profile=record&meta_i=312686
- Gowrishankar K, Birtwistle L, Micklethwaite K. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells. Mamm Genome. 2018 Jul 9;29(11–12): 739–756.
- Wohlfarth P, Worel N, Hopfinger G. Chimeric antigen receptor Tcell therapy-a hematological success story. Memo. 2018;11(2):116–121.
- Gross G, Eshhar Z. Therapeutic potential of T cell Chimeric Antigen Receptors (CARs) in cancer treatment: counteracting off-tumor toxicities for safe CAR T cell therapy. Annu Rev Pharmacol Toxicol. 2016;56:59–83.
- Cornel AM, Mimpen IL, Nierkens S, et al. I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. Cancers (Basel). 2020 Jul 2;12(7). DOI:https://doi.org/10.3390/cancers12071760
- Dotti G, Gottschalk S, Savoldo B, et al. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014 Jan;257(1):107–126.
- Cheadle EJ, Gornall H, Baldan V, et al. CAR T cells: driving the road from the laboratory to the clinic. Immunol Rev. 2014 Jan;257(1):91–106.
- Heyman B, Yang Y. New developments in immunotherapy for lymphoma. Cancer Biol Med. 2018 Aug;15(3):189–209.
- Harris DT, Kranz DM. Adoptive T cell therapies: a comparison of T cell receptors and chimeric antigen receptors. Trends Pharmacol Sci. 2016 Mar;37(3):220–230.
- Muhammad N, Mao Q, Xia H. CAR T-cells for cancer therapy. Biotechnol Genet Eng Rev. 2017 Oct;33(2):190–226.
- Wilkie S, Picco G, Foster J, et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Iimmunol. 2008 Apr 1;180(7):4901–4909.
- Guest RD, Hawkins RE, Kirillova N, et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother. 2005 May-Jun;28(3):203–211.
- Ramos CA, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther. 2011 Jul;11(7):855–873.
- Irving BA, Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell. 1991 Mar 8;64(5):891–901.
- Finney HM, Lawson AD, Bebbington CR, et al. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Iimmunol. 1998 Sep 15;161(6):2791–2797.
- Finney HM, Akbar AN, Lawson AD. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Iimmunol. 2004 Jan 1;172(1):104–113.
- Tammana S, Huang X, Wong M, et al. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther. 2010 Jan;21(1):75–86.
- Hombach AA, Abken H. Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. Int J Cancer. 2011 Dec 15;129(12):2935–2944.
- Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145–1154.
- Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev. 2014 Jan;257(1):83–90.
- Chmielewski M, Kopecky C, Hombach AA, et al. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011 Sep 1;71(17):5697–5706.
- Chmielewski M, Abken H. CAR T cells releasing IL-18 convert to T-Bet(high) FoxO1(low) effectors that exhibit augmented activity against advanced solid tumors. Cell Rep. 2017 Dec 12;21(11):3205–3219.
- Pegram HJ, Lee JC, Hayman EG, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012 May 3;119(18):4133–4141.
- Clinicaltrials.gov. Search of: fourth generation CAR - list results - ClinicalTrials.gov. [Online]; 2020. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=fourth+generation+CAR&cntry=&state=&city=&dist=
- Levine BL, Miskin J, Wonnacott K, et al. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017 Mar 17;4:92–101.
- van Schalkwyk MC, Papa SE, Jeannon JP, et al. Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. Hum Gene Ther Clin Dev. 2013 Sep;24(3):134–142.
- Ghosh A, Smith M, James SE, et al. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat Med. 2017 Feb;23(2):242–249.
- Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010 Nov 18;116(20):4099–4102.
- Singh N, Perazzelli J, Grupp SA, et al. Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies. Sci Transl Med. 2016 Jan 6;8(320):320ra3.
- Townsend MH, Shrestha G, Robison RA, et al. The expansion of targetable biomarkers for CAR T cell therapy. J Exp Clin Cancer Res. 2018 Jul 21;37(1):163.
- Chow VA, Shadman M, Gopal AK. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Blood. 2018 Aug 23;132(8):777–781.
- Qasim W, Zhan H, Samarasinghe S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017 Jan 25;9:374.
- Vormittag P, Gunn R, Ghorashian S, et al. A guide to manufacturing CAR T cell therapies. Curr Opin Biotechnol. 2018 Oct;53:164–181.
- Whilding LM, Maher J. CAR T-cell immunotherapy: the path from the by-road to the freeway? Mol Oncol. 2015 Dec;9(10):1994–2018.
- Tesfaye M, Savoldo B. Adoptive cell therapy in treating pediatric solid tumors. Curr Oncol Rep. 2018 Aug 1;20(9):73.
- Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010 Apr;18(4):843–851.
- Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol. 2019;10:128.
- Zhang E, Yang P, Gu J, et al. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy. J Hematol Oncol. 2018 Aug 13;11(1):102.
- Wilkie S, van Schalkwyk MC, Hobbs S, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol. 2012 Oct;32(5):1059–1070.
- Kloss CC, Condomines M, Cartellieri M, et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2013 Jan;31(1):71–75.
- Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018 Oct;8(10):1219–1226.
- Hegde M, Mukherjee M, Grada Z, et al. Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J Clin Invest. 2016 Aug 1;126(8):3036–3052.
- Elahi R, Khosh E, Tahmasebi S, et al. Immune cell hacking: challenges and clinical approaches to create smarter generations of chimeric antigen receptor T cells. Front Immunol. 2018;9:1717.
- Davies DM, Foster J, Van Der Stegen SJ, et al. Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Mol Med. 2012 May;9(18):565–576.
- Pishali Bejestani E, Cartellieri M, Bergmann R, et al. Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model. Oncoimmunology. 2017;6(10):e1342909.
- Shum T, Kruse RL, Rooney CM. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities. Expert Opin Biol Ther. 2018 Jun;18(6):653–664.
- Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013 Dec 11;5(215):215ra172.
- Morsut L, Roybal KT, Xiong X, et al. Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell. 2016 Feb 11;164(4):780–791.
- Roybal KT, Williams JZ, Morsut L, et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell. 2016 Oct 6;167(2):419–432 e16.
- Jindal V, Arora E, Gupta S. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors. Med Oncol. 2018 May 5;35(6):87.
- Miao H, Choi BD, Suryadevara CM, et al. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PloS One. 2014;9(4):e94281.
- Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008 Sep 1;26(25):4189–4199.
- Gulati I, Patel H, Prabhakar B, et al. Current translational insights into MGMT methylation regulating temozolomide sensitivity and resistance in glioblastoma multiforme. Curr Pharmacogenomics Pers Med. 2020;17(2):1–18.
- O’Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017 Jul 19;9(399):eaaa0984.
- Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235.
- Budde LE, Berger C, Lin Y, et al. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PloS One. 2013;8(12):e82742.
- Casucci M, Falcone L, Camisa B, et al. Extracellular NGFR spacers allow efficient tracking and enrichment of fully functional CAR-T cells co-expressing a suicide gene. Front Immunol. 2018;9:507.
- Traversari C, Marktel S, Magnani Z, et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood. 2007 Jun 1;109(11):4708–4715.
- Clinicaltrials.gov. Search of: caspase 9 CAR T-cells - list results - ClinicalTrials.gov. [Online]; 2020. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=caspase+9+CAR+T-cells&cntry=&state=&city=&dist=
- Akahori Y, Wang L, Yoneyama M, et al. Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can beenhanced by vaccination. Blood. 2018 Sep 13;132(11):1134–1145.
- Clinicaltrials.gov. iC9-GD2-CAR-VZV-CTLs/refractory or metastatic GD2-positive sarcoma and neuroblastoma - full text view - ClinicalTrials.gov. [Online]; 2020 [cited 2020 Jan 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT01953900?term=NCT01953900&draw=2&rank=1.
- Kosti P, Maher J, Arnold JN. Perspectives on chimeric antigen receptor T-cell immunotherapy for solid tumors. Front Immunol. 2018;9:1104.
- Rosewell Shaw A, Suzuki M. Oncolytic viruses partner with T-cell therapy for solid tumor treatment. Front Immunol. 2018;9:2103.
- Watanabe K, Luo Y, Da T, et al. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight. 2018 Apr 5;3(7). DOI:https://doi.org/10.1172/jci.insight.99573
- Nishio N, Dotti G. Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors. Oncoimmunology. 2015 Feb;4(2):e988098.
- Wing A, Fajardo CA, Posey AD Jr., et al. Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager. Cancer Immunol Res. 2018 May;6(5):605–616.
- Caruana I, Savoldo B, Hoyos V, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. Nature Med. 2015 May;21(5):524–529.
- Di Stasi A, De Angelis B, Rooney CM, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009 Jun 18;113(25):6392–6402.
- Moon EK, Carpenito C, Sun J, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res off J Am Assoc Cancer Res. 2011 Jul 15;17(14):4719–4730.
- Whilding LM, Halim L, Draper B, et al. CAR T-cells targeting the integrin alphavbeta6 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies. Cancers (Basel). 2019 May 14;11:5.
- Adusumilli PS, Cherkassky L, Villena-Vargas J, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014 Nov 5;6(261):261ra151.
- Adusumilli PS, Zauderer MG, Rusch VW, et al. A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: safety and efficacy. Cancer Res. 2019. 79(13 Supplement). Abstract CT036.
- Murad JP, Kozlowska AK, Lee HJ, et al. Effective targeting of TAG72(+) peritoneal ovarian tumors via regional delivery of CAR-engineered T cells. Front Immunol. 2018;9:2268.
- Hege KM, Bergsland EK, Fisher GA, et al. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 2017;5:22.
- Nellan A, Rota C, Majzner R, et al. Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J Immunother Cancer. 2018 Apr 30;6(1):30.
- Priceman SJ, Tilakawardane D, Jeang B, et al. Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2(+) breast cancer metastasis to the brain. Clin Cancer Res off J Am Assoc Cancer Res. 2018 Jan 1;24(1):95–105.
- Brown CE, Badie B, Barish ME, et al. Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res off J Am Assoc Cancer Res. 2015 Sep 15;21(18):4062–4072.
- Brown CE, Aguilar B, Starr R, et al. Optimization of IL13Ralpha2-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma. Mol Ther. 2018 Jan 3;26(1):31–44.
- Clinicaltrials.gov. Phase I trial: T4 immunotherapy of head and neck cancer - full text view - ClinicalTrials.gov. [Online]; 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT01818323?term=NCT01818323&draw=2&rank=1
- Clinicaltrials.gov. Search of: regional delivery CAR T-cells - list results - ClinicalTrials.gov. [Online]; 2020 [cited 2020 Jan 20]. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=Regional+delivery+CAR+T-cells&cntry=&state=&city=&dist=
- Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell. 2003 Dec;4(6):431–436.
- Newick K, O’Brien S, Sun J, et al. Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase A localization. Cancer Immunol Res. 2016 Jun;4(6):541–551.
- Rupp LJ, Schumann K, Roybal KT, et al. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017 Apr 7;7(1):737.
- Zhang Y, Zhang X, Cheng C, et al. CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells. Front Med. 2017 Dec;11(4):554–562.
- Ren J, Zhang X, Liu X, et al. A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget. 2017 Mar 7;8(10):17002–17011.
- Clinicaltrials.gov. NY-ESO-1-redirected CRISPR (TCRendo and PD1) edited T cells (NYCE T cells) - full text view - ClinicalTrials.gov. [Online]; 2020 [cited 2020 Jan 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03399448?term=NCT03399448&draw=2&rank=1
- Clinicaltrials.gov. Study of PD-1 gene-knocked out mesothelin-directed CAR-T cells with the conditioning of PC in mesothelin positive multiple solid tumors - full text view - ClinicalTrials.gov. [Online]; 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT03747965?term=NCT03747965&draw=2&rank=1
- Clinicaltrials.gov. Study of CRISPR-Cas9 mediated PD-1 and TCR gene-knocked out mesothelin-directed CAR-T cells in patients with mesothelin positive multiple solid tumors. - full text view - ClinicalTrials.gov. [Online]; 2020 [cited 2020 Jan 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03545815?term=NCT03545815&draw=2&rank=1
- Sengupta S, Katz SC, Sengupta S, et al. Glycogen synthase kinase 3 inhibition lowers PD-1 expression, promotes long-term survival and memory generation in antigen-specific CAR-T cells. Cancer Lett. 2018 Oct 1;433:131–139.
- Suarez ER, Chang de K, Sun J, et al. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget. 2016 Jun 7;7(23):34341–34355.
- John LB, Devaud C, Duong CP, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res off J Am Assoc Cancer Res. 2013 Oct 15;19(20):5636–5646.
- Clinicaltrials.gov. IL13Ralpha2-targeted Chimeric Antigen Receptor (CAR) T cells with or without nivolumab and ipilimumab in treating patients with recurrent or refractory glioblastoma - full text view - ClinicalTrials.gov. [Online]; 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04003649?term=NCT04003649&draw=2&rank=1
- Yin Y, Boesteanu AC, Binder ZA, et al. Checkpoint blockade reverses anergy in IL-13Ralpha2 humanized scfv-based CAR T cells to treat murine and canine gliomas. Mol Ther Oncolytics. 2018 Dec 21;11:20–38.
- Clinicaltrials.gov. Autologous T cells redirected to EGFRVIII-with a chimeric antigen receptor in patients with EGFRVIII+ glioblastoma - full text view - ClinicalTrials.gov. [Online]; 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT02209376?term=NCT02209376&draw=1&rank=1
- Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005 Sep;23(9):1126–1136.
- Clinicaltrials.gov. Search of: immune checkpoint expressing CAR - list results - ClinicalTrials.gov. [Online]; 2020. Available from: https://clinicaltrials.gov/ct2/results?cond=&term=immune+checkpoint+expressing+CAR&cntry=&state=&city=&dist=
- Liu X, Ranganathan R, Jiang S, et al. A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res. 2016 Mar 15;76(6):1578–1590.
- Bhattacharyya S, Saha J. Tumour oxidative stress and host T cell response: cementing the dominance. Scand J Immunol. 2015 Dec;82(6):477–488.
- Ligtenberg MA, Mougiakakos D, Mukhopadhyay M, et al. Coexpressed catalase protects chimeric antigen receptor-redirected T cells as well as bystander cells from oxidative stress-induced loss of antitumor activity. J Iimmunol. 2016 Jan 15;196(2):759–766.
- Tu E, Chia PZ, Chen W. TGFbeta in T cell biology and tumor immunity: angel or devil? Cytokine Growth Factor Rev. 2014 Aug;25(4):423–435.
- Quatromoni JG, Wang Y, Vo DD, et al. T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFbeta) signaling mediate superior tumor regression in an animal model of adoptive cell therapy. J Transl Med. 2012 Jun 19;10:127.
- Kloss CC, Lee J, Zhang A, et al. Dominant-negative TGF-beta receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther. 2018 Jul 5;26(7):1855–1866.
- Loeffler M, Kruger JA, Niethammer AG, et al. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest. 2006 Jul;116(7):1955–1962.
- Kakarla S, Chow KK, Mata M, et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther. 2013 Aug;21(8):1611–1620.
- Petrausch U, Schuberth PC, Hagedorn C, et al. Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). BMC Cancer. 2012 Dec 22;12:615.
- Tran E, Chinnasamy D, Yu Z, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013 Jun 3;210(6):1125–1135.
- Sukumaran S, Watanabe N, Bajgain P, et al. Enhancing the potency and specificity of engineered T cells for cancer treatment. Cancer Discov. 2018 Aug;8(8):972–987.
- Frumento G, Rotondo R, Tonetti M, et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med. 2002 Aug 19;196(4):459–468.
- Ninomiya S, Narala N, Huye L, et al. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015 Jun 18;125(25):3905–3916.
- Arab S, Kheshtchin N, Ajami M, et al. Increased efficacy of a dendritic cell-based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor. Tumour Biol. 2017 Mar;39(3):1010428317695021.
- Beavis PA, Henderson MA, Giuffrida L, et al. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest. 2017 Mar 1;127(3):929–941.
- Siriwon N, Kim YJ, Siegler E, et al. CAR-T cells surface-engineered with drug-encapsulated nanoparticles can ameliorate intratumoral T-cell hypofunction. Cancer Immunol Res. 2018 Jul;6(7):812–824.
- Gao S, Yang D, Fang Y, et al. Engineering nanoparticles for targeted remodeling of the tumor microenvironment to improve cancer immunotherapy. Theranostics. 2019;9(1):126–151.
- Fda.gov. Precision medicine. [Online]; 2018. Available from: https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/PrecisionMedicine-MedicalDevices/default.htm
- Nair S, Kong AT. Emerging roles for clinical pharmacometrics in cancer precision medicine. Current Pharmacol Rep. 2018 Jun;4(3):276–283.
- Allofus.nih.gov. Program overview - all of us national institutes of health. [Online]; 2018. Available from: https://allofus.nih.gov/about/about-all-us-research-program
- Abraham TS, Snook AE. The swinging pendulum of cancer immunotherapy personalization. Per Med. 2017 May;14(3):259–270.
- Stepanov AV, Markov OV, Chernikov IV, et al. Autocrine-based selection of ligands for personalized CAR-T therapy of lymphoma. Sci Adv. 2018 Nov;4(11):eaau4580.
- Hernandez I, Prasad V, Gellad WF. Total costs of chimeric antigen receptor T-cell immunotherapy. JAMA Oncol. 2018 Jul 1;4(7):994–996.
- Forsberg MH, Das A, Saha K, et al. The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL. Ther Clin Risk Manag. 2018;14:1573–1584.
- England N. NHS England NHS England announces groundbreaking new personalised therapy for children with cancer. [Online]. England.nhs.uk; 2018. Available from: https://www.england.nhs.uk/2018/09/nhs-england-announces-groundbreaking-new-personalised-therapy-for-children-with-cancer/
- England N. NHS England NHS England strikes deal for ground breaking cancer treatment in a new European first. [Online]. England.nhs.uk; 2018. Available from: https://www.england.nhs.uk/2018/10/nhs-england-strikes-deal-for-ground-breaking-cancer-treatment-in-a-new-european-first/
- Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87–108.
- Depil S, Duchateau P, Grupp SA, et al. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020 Mar;19(3):185–199.
- clinicaltrials.gov. alloSHRINK - standard chemotherapy regimen and immunotherapy with allogeneic NKG2D-based CYAD-101 chimeric antigen receptor t-cells - full text view - ClinicalTrials.gov. [Online]; 2020 [cited 2020 Jan 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT03692429
- Wang L, Dou M, Ma Q, et al. Chimeric antigen receptor (CAR)-modified NK cells against cancer: opportunities and challenges. Int Immunopharmacol. 2019 Jun 26;74:105695.
- Clinicaltrials.gov. Search of: CAR T cell therapy cancer - list results - ClinicalTrials.gov. [Online]. Available from: https://clinicaltrials.gov/ct2/results?cond=cancer&term=CAR+T+Cell+therapy&cntry=&state=&city=&dist=